PL407947A1 - Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania - Google Patents

Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania

Info

Publication number
PL407947A1
PL407947A1 PL407947A PL40794714A PL407947A1 PL 407947 A1 PL407947 A1 PL 407947A1 PL 407947 A PL407947 A PL 407947A PL 40794714 A PL40794714 A PL 40794714A PL 407947 A1 PL407947 A1 PL 407947A1
Authority
PL
Poland
Prior art keywords
oligonucleotide
polyethyleneimine
application
oriented
obtaining
Prior art date
Application number
PL407947A
Other languages
English (en)
Inventor
Justyna Meissner
Monika Toporkiewicz
Kazimierz Kuliczkowski
Aleksander Czogalla
Aleksander Sikorski
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL407947A priority Critical patent/PL407947A1/pl
Priority to PCT/PL2015/050010 priority patent/WO2015160270A1/en
Publication of PL407947A1 publication Critical patent/PL407947A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina charakteryzująca się tym, że stosunek oligonukleotydu do polietylenoiminy zawiera się w przedziale od 1:10 do 1:3 a kompleks otoczony jest dwuwarstwą lipidową umożliwiającą przyłączenie cząsteczki rozpoznającej marker powierzchniowy komórek patologicznych oraz jej sposób otrzymywania i zastosowanie.
PL407947A 2014-04-18 2014-04-18 Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania PL407947A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL407947A PL407947A1 (pl) 2014-04-18 2014-04-18 Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania
PCT/PL2015/050010 WO2015160270A1 (en) 2014-04-18 2015-04-18 Targeted liposomal form of oligonucleotide-polyethyleneimine complex, its use and method of obtaining

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL407947A PL407947A1 (pl) 2014-04-18 2014-04-18 Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania

Publications (1)

Publication Number Publication Date
PL407947A1 true PL407947A1 (pl) 2015-10-26

Family

ID=54324350

Family Applications (1)

Application Number Title Priority Date Filing Date
PL407947A PL407947A1 (pl) 2014-04-18 2014-04-18 Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania

Country Status (2)

Country Link
PL (1) PL407947A1 (pl)
WO (1) WO2015160270A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL245879B1 (pl) * 2021-05-31 2024-10-28 Acellmed Spolka Z Ograniczona Odpowiedzialnoscia Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania
CN115624539A (zh) * 2022-12-16 2023-01-20 首都医科大学附属北京朝阳医院 一种脂质纳米颗粒及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20080213350A1 (en) * 2007-02-20 2008-09-04 Texas Tech University System Encapsulation of nucleic acids in liposomes
PL208054B1 (pl) * 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie

Also Published As

Publication number Publication date
WO2015160270A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
EP2954313A4 (en) IMAGING FOR DETERMINING THE PHYSICAL ATTRIBUTES OF CRUSTACEANS
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
MX2017003794A (es) Formulaciones estables de lipidos y liposomas.
EP3509605A4 (en) LIPSOMAL ANTI-CANCER COMPOSITIONS
PL3142785T3 (pl) Sposób wytwarzania alkenoli i ich zastosowanie do wytwarzania 1,3- butadienu
PL3091003T3 (pl) Pochodna 1,2‑naftochinonu i sposób jej przygotowania
PL407166A1 (pl) Zawiesina nanopłatków tlenku grafenu w wodzie, jej zastosowanie i sposób jej otrzymywania
IL262728A (en) Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
PL3515918T3 (pl) Sposób wytwarzania 2-egzo-(2-metylobenzyloksy)-1-me¬tylo-4-izopropylo-7-oksabicyklo[2.2.1]heptanu
PL3138555T3 (pl) Kompozycja liposomowa i sposób jej wytwarzania
TR201904972T4 (tr) Yenilebilir yağda su emülsiyonları ve bu emülsiyonların hazırlanması için bir işlem.
EA201690263A1 (ru) Улучшенные способы получения перампанеля
PL407947A1 (pl) Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MX387328B (es) Proceso para la preparacion de la forma i de anhidrato de boscalid y la forma ii de anhidrato de boscalid
ITUA20161550A1 (it) Procedimento per la produzione di RNA
EP2955228A4 (en) RNA WITH LOW INTERFERENCE TO INHIBIT INTRA-CELLULAR EXPRESSION OF THE RIBOSOMAL PROTEIN S3
ES1111380Y (es) Máquina para el labrado intercepa de la tierra
UY34622A (es) Proceso para la preparación de compuestos con estructura carboxamida
TH1301006568B (th) วิธีการสำหรับการผลิตไดโอเลฟินที่ถูกคอนจูเกตและชุดเครื่องสำหรับการผลิต
TWM417534U (en) BB bullethead fixed structure
ES2464692B1 (es) Composición para la mejora de la respuesta sexual femenina
TH1401006457B (th) เครื่องเพื่อการก่อเกิดน้ำที่ได้รับการอิเล็กโทรไลต์แบบมีฟองละเอียด และวิธีการสำหรับการก่อเกิดน้ำที่ได้รับอิเล็กโทรไลต์แบบมีฟองละเอียด
CN302353304S (zh) 炸面饼圈